Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Subcutaneous LY2127399 in Systemic Lupus Erythematosus
jRCT2080221906Phase 3
- Sponsor
- Parexel
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tabalumab in systemic lupus erythematosus (SLE) (3 arms), sponsored by Parexel.
02
Drugs
tabalumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2080221906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221906.